S-1: ZyVersa Therapeutics Secures Up to $10 Million Equity Funding Amidst Going Concern Doubts and Nasdaq Delisting Threat

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, has entered into an equity purchase agreement to raise up to $10 million, while simultaneously facing substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing compliance challenges.

Summary

• ZyVersa Therapeutics has entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, allowing the company to sell up to $10 million of its common stock over a period ending June 24, 2027.
• The company will also issue up to 426,829 Commitment Shares to Williamsburg as consideration for entering the agreement.
• The S-1 filing registers for resale up to 17,500,008 shares of common stock, comprising 17,073,179 EPA Shares and 426,829 Commitment Shares.
• As of June 30, 2025, the company had 4,873,456 shares of common stock outstanding; assuming the full amount available under the Purchase Agreement is sold, the total outstanding shares would increase to 22,373,464.
• The company expects to receive up to $9,992,500 in net proceeds from the sale of EPA Shares, which will be used for working capital and general corporate purposes.
• ZyVersa is a clinical-stage biopharmaceutical company with two proprietary drug development platforms: VAR 200 for renal diseases (in Phase 2a for diabetic kidney disease, with plans for FSGS) and IC 100 for inflammatory conditions (in preclinical development, with planned IND submission in H2-2025 for obesity with cardiometabolic complications).
• The company's independent registered public accounting firm's report for the year ended December 31, 2024, contains an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern.
• ZyVersa's current cash on hand is deemed 'vastly inadequate' and sufficient only on a 'month-to-month basis'.
• The company has a history of non-compliance with Nasdaq's $1.00 minimum bid price requirement, having received a notice on February 5, 2024, regaining compliance on May 13, 2024, but receiving another non-compliance notice on May 27, 2025.
• Due to prior reverse stock splits (1-for-35 on December 4, 2023, and 1-for-10 on April 24, 2024), the company is not eligible for the customary cure period for the latest Nasdaq deficiency and has filed an appeal.

Sentiment

Score: 3

Explanation: While the securing of a potential $10 million capital raise provides a lifeline, the overall sentiment is negative due to the explicit 'going concern' doubt, the 'vastly inadequate' cash position, and the severe, recurring Nasdaq compliance issues that threaten delisting. The significant potential dilution for existing shareholders further weighs down the sentiment, indicating a company in a precarious financial state despite the funding attempt.

Positives

• Secured an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, providing access to up to $10 million in gross proceeds for working capital and general corporate purposes.
• VAR 200, a cholesterol efflux mediator, is in clinical development (Phase 2a trial initiated for diabetic kidney disease) with pharmacologic proof-of-concept data in animal models for multiple renal indications.
• IC 100, an inflammasome ASC inhibitor, is nearing completion of preclinical development with a planned IND submission in H2-2025 and preclinical data supporting multiple inflammatory indications.

Negatives

• Independent auditors' report for the year ended December 31, 2024, expresses substantial doubt about the company's ability to continue as a going concern.
• Current cash on hand is 'vastly inadequate' and only sufficient to meet anticipated cash requirements on a 'month-to-month basis'.
• The company has a history of failing to comply with Nasdaq's minimum bid price requirement and recently received another non-compliance notice on May 27, 2025.
• Due to previous reverse stock splits, the company is not eligible for the customary cure period for the latest Nasdaq deficiency, increasing the risk of delisting.
• The issuance of up to 17,500,008 shares to Williamsburg Venture Holdings, LLC, represents significant potential dilution to existing stockholders, potentially increasing outstanding shares from 4,873,456 to 22,373,464.
• The actual gross proceeds from the equity purchase agreement may be less than $10 million, which could further impact liquidity.

Risks

• Investing in the company's securities involves a high degree of risk, with investors potentially losing all of their investment.
• The actual number of shares sold under the Purchase Agreement and the resulting gross proceeds are uncertain and may be less than $10 million, impacting future liquidity.
• Limitations in the Purchase Agreement, such as the 19.99% beneficial ownership cap (unless stockholder approval is obtained), may restrict the company's ability to utilize the full $10 million arrangement.
• Investors purchasing shares at different times may pay different prices and experience varying levels of dilution.
• The issuance and resale of a significant number of shares by the Selling Stockholder may cause the trading price of the common stock to decline and be highly volatile.
• Failure to maintain Nasdaq's continued listing requirements could lead to delisting, substantially decreasing trading, adversely affecting market liquidity, hindering financing, and potentially eroding investor confidence.
• The company's ability to continue as a going concern is in substantial doubt due to a history of net losses and inadequate cash position.
• Substantial additional capital will be needed to develop and commercialize product candidates, and there are no commitments for such financing, which may not be available on acceptable terms or at all.
• Raising additional funds through equity offerings will dilute existing stockholders, while debt financing could impose restrictive covenants and divert funds from R&D.
• Reliance on third parties for technology, intellectual property, and clinical development poses operational risks.
• General economic and financial market conditions, including supply chain disruptions and inflationary pressures, could adversely affect the business.
• The possibility of an economic recession and geopolitical changes present additional risks.
• The outbreak of infectious diseases like COVID-19 or new pandemics could disrupt business plans, product development, and clinical trials.
• Litigation and regulatory enforcement risks, including diversion of management time and attention, could incur additional costs and demands.

Future Outlook

The company plans to advance its Inflammasome ASC Inhibitor IC 100 toward an Investigational New Drug (IND) submission in the second half of 2025, followed by the initiation of a Phase 1 trial in healthy overweight patients. Preclinical studies for IC 100 are underway in Alzheimer's and Parkinson's diseases, and the company is preparing to initiate an IND-enabling preclinical study in an animal model of diet-induced obesity. The company will use proceeds from the equity purchase agreement for working capital and general corporate purposes to support its business plans, including further research and development.

Management Comments

• Management believes current cash on hand is vastly inadequate to support business plans and substantial additional funding will be needed.
• Management will have broad discretion in the application of the net proceeds from the equity offering.
• Management has appealed the Nasdaq Staff's determination regarding non-compliance with the minimum bid price requirement.

Industry Context

ZyVersa Therapeutics operates in the highly competitive and regulated biopharmaceutical industry, specifically focusing on developing drugs for chronic renal and inflammatory diseases with high unmet medical needs. Its strategy of 'indication expansion' for its two proprietary drug development platforms (VAR 200 and IC 100) aligns with a common approach in the biopharma sector to maximize commercial potential from foundational research, particularly for rare diseases and conditions with broad applicability.

Comparison to Industry Standards

• NA The document does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks or industry standards.

Corporate Governance

Legal Proceedings

• The company has received a letter from the Nasdaq Staff notifying it of non-compliance with the Minimum Bid Price Requirement ($1.00) on May 27, 2025, and has filed an appeal of this determination.

Stakeholder Impact

• Shareholders face significant potential dilution (up to 78% of total outstanding shares) from the issuance of shares under the Equity Purchase Agreement, which could negatively impact the value of their holdings.
• Shareholders are at high risk of losing all or part of their investment due to the company's 'going concern' doubt and precarious financial position.
• Shareholders face increased risk of their common stock being delisted from Nasdaq due to recurring non-compliance with listing requirements and ineligibility for a customary cure period.
• Employees may face job insecurity if the company's financial challenges and 'going concern' issues are not resolved through sustained funding and successful product development.

Next Steps

• File a Current Report on Form 8-K with the SEC, including the Transaction Documents as exhibits.
• File an initial Registration Statement on Form S-1 covering the maximum number of Registrable Securities by October 21, 2025.
• Use commercially reasonable best efforts to have the Initial Registration Statement and any amendments declared effective by the SEC.
• File prospectuses and prospectus supplements as required by applicable securities regulations.
• Amend the Initial Registration Statement or file a new Registration Statement if the number of shares available is insufficient to cover all Registrable Securities.
• Keep all Registration Statements effective and available for resale of Registrable Securities until the end of the Registration Period.
• Secure the listing of all Put Shares and Commitment Shares on The Nasdaq Capital Market.
• Maintain the services of the Transfer Agent and registrar for common stock.
• Utilize net proceeds from the equity offering for working capital and general corporate purposes.
• Proceed with the planned Investigational New Drug (IND) submission for IC 100 in H2-2025.
• Initiate a Phase 1 trial for IC 100 in healthy overweight patients (BMI 27-30) following IND submission.
• Prepare to initiate an IND-enabling preclinical study in an animal model of diet-induced obesity for IC 100.
• Await the outcome of the appeal regarding the Nasdaq Staff's delisting determination.

Key Dates

Recommendation

Keywords

Biopharmaceutical, Clinical Stage, SEC Filing, S-1, Equity Purchase Agreement, Capital Raise, Dilution, Nasdaq Compliance, Going Concern, VAR 200, IC 100, Renal Disease, Inflammatory Disease, Focal Segmental Glomerulosclerosis, Diabetic Kidney Disease, Obesity, Cardiometabolic Complications, IND Submission, Phase 2a Trial, Preclinical Development, ZVSA